THE PRETREATMENT PROSTATE-SPECIFIC ANTIGEN DOUBLING TIME: CLINICAL AND PROGNOSTIC VALUES IN PATIENTS WITH PROSTATE CANCER
https://doi.org/10.17650/1726-9776-2014-10-1-44-48
Abstract
The purpose of the study – to estimate the clinical and prognostic values of the pretreatment prostate specific antigen (PSA) doubling time (PSADT) in patients with prostate cancer.
Materials and methods. Pretreatment PSADT and follow-up information was compiled on 912 men who were treated with external beam radiation therapy (RT). PSADT were compared with the clinical tumor category, Gleason score, PSA level at diagnosis, as well as the age and level of education of patients. The pretreatment PSADT also were compared with survival rates of patients.
Results. In the current study the correlation between the PSADT and the degree of tumor progression was shown. PSADT decreased with the increase of clinical tumor stage, Gleason score and PSA level at diagnosis. Moreover, in the study the prognostic value of PSADT was confirmed. The statistically and clinically significant associations between the PSADT and all-cause mortality in the setting of PSA failure following have been described.
About the Authors
G. M. Zharinov
Russian Research Center of Radiology and Surgical Technologies, Ministry of Health of the Russian, St. Petersburg
Russian Federation
Russian Federation
O. A. Bogomolov
Russian Research Center of Radiology and Surgical Technologies, Ministry of Health of the Russian, St. Petersburg
Russian Federation
Russian Federation
References
1. Матвеев Б. П. Клиническая онкоурология. М.: ИД «АБВ-пресс», 2011; с. 495–525.
2. Pearson J. D., Carter H. B. Natural history of changes in prostate specific antigen in early stage prostate cancer. J Urol 1994;152:1743–8.
3. Choo R., Klotz L., Deboer G. et al. Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-tointermediate grade, prostate carcinoma. BJU Int 2004;94(3):295–8.
4. Ramirez M. L., Nelson E. C., Devere White R. W. et al. Current applications for prostate-specific antigen doubling time. Eur Urol 2008 Aug;54(2):291–300.
5. Arlen P.M., Bianco F., Dahut W.L. et al. Prostate-Specific Antigen Working Group’s Guidelines on PSA Doubling Time. J Urol 2008;179(6):2181–6.
6. D’Amico A. V., Moul J. W., Carroll P. R. et al. Surrogate end point for prostate cancerspecific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003;95:1376–83.
7. Freedland S. J., Humphreys E. B., Mangold L. A. et al. Risk of prostate cancerspecific mortality following biochemical recurrence after radical prostatectomy. JAMA2005;294:433–9.
8. Khatami A., Aus G., Damber J. E. et al. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 2007;120:170–4.
9. Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol 2005;23:8165–9.
10. Жаринов Г. М., Некласова Н. Ю., Зимин А. А. Клиническое и прогностическое значение исходного времени удвоения простатспецифического антигена у больных раком предстательной железы. Вопр онкол 2012;58(6):817–20.
11. Lee A. K., Levy L. B., Cheung R. et al. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Int J Radiat Oncol Biol Phys 2005;63(2):456–62.
12. Sengupta S., Myers R. P., Slezak J. M. et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005;174:2191–6.
13. Freedland S. J., Dorey F., Aronson W. J. Preoperative PSA velocity and doubling time do not predict adverse pathologic features or biochemical recurrence after radical prostatectomy. Urology 2001;57:476–80.
14. Goluboff E. T., Heitjan D. F., DeVries G. M. et al. Pretreatment prostate specific antigen doubling times: use in patients before radical prostatectomy. J Urol 1997;158:1876–78.
15. Memorial Sloan-Kettering Cancer Center cancer information: prostate nomogram. http://www.mskcc.org/mskcc/html/10088.cfm.
16. Cancer Facts & Figures 2011. American Cancer Society, Inc. Surveillance Research.P:25. http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2011.
17. Adler N., Pantell M. S., O’Donovan A. et al. Educational attainment and late life telomere length in the Health, Aging and Body Composition Study. Brain Behav Immunol 2013;27:15–21.
18. Жаринов Г.М., Гущин В.А. Скорость роста и клеточная потеря при раке шейки матки. Вопр онкол 1989;35(1):21–5.
19. Жаринов Г.М., Пожарисский К.М., Винокуров В.Л. и др. Некоторые кинетические характеристики рака шейки матки. Вопр онкол 2009;55(2): 196–200.
Review
For citations:
Zharinov G.M., Bogomolov O.A. THE PRETREATMENT PROSTATE-SPECIFIC ANTIGEN DOUBLING TIME: CLINICAL AND PROGNOSTIC VALUES IN PATIENTS WITH PROSTATE CANCER. Cancer Urology. 2014;10(1):44-48. (In Russ.) https://doi.org/10.17650/1726-9776-2014-10-1-44-48
Views:
2056
Email this article 